View Item 

Show simple item record

Management of Adverse Events Following Treatment With Anti‐Programmed Death‐1 Agents
dc.contributor.authorWeber, Jeffrey S.
dc.contributor.authorPostow, Michael
dc.contributor.authorLao, Christopher D.
dc.contributor.authorSchadendorf, Dirk
dc.date.accessioned2017-12-15T16:49:14Z
dc.date.available2017-12-15T16:49:14Z
dc.date.issued2016-10
dc.identifier.citationWeber, Jeffrey S.; Postow, Michael; Lao, Christopher D.; Schadendorf, Dirk (2016). "Management of Adverse Events Following Treatment With Anti‐Programmed Death‐1 Agents." The Oncologist 21(10): 1230-1240.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/140047
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherDrug‐related side effects and adverse reactions
dc.subject.otherMelanoma
dc.subject.otherPembrolizumab
dc.subject.otherNivolumab
dc.subject.otherProgrammed cell death 1 receptor
dc.titleManagement of Adverse Events Following Treatment With Anti‐Programmed Death‐1 Agents
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
dc.contributor.affiliationotherUniversity Hospital Essen, Essen, Germany
dc.contributor.affiliationotherLaura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York, USA
dc.contributor.affiliationotherMemorial Sloan Kettering Cancer Center, New York, New York, USA
dc.contributor.affiliationotherWeill Cornell Medical College, New York, New York, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/140047/1/onco1230.pdf
dc.identifier.doi10.1634/theoncologist.2016-0055
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceRJ Motzer, BI Rini, DF McDermott. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol. 2015; 33: 1430 – 1437.
dc.identifier.citedreferenceFS Hodi, SJ O’Day, DF McDermott. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711 – 723.
dc.identifier.citedreferenceC Robert, GV Long, B Brady. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372: 320 – 330.
dc.identifier.citedreferenceJS Weber, SP D’Angelo, D Minor. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti‐CTLA‐4 treatment (CheckMate 037): A randomised, controlled, open‐label, phase 3 trial. Lancet Oncol. 2015; 16: 375 – 384.
dc.identifier.citedreferenceC Robert, J Schachter, GV Long. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372: 2521 – 2532.
dc.identifier.citedreferenceMA Postow, J Chesney, AC Pavlick. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372: 2006 – 2017.
dc.identifier.citedreferenceJ Larkin, V Chiarion‐Sileni, R Gonzalez. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373: 23 – 34.
dc.identifier.citedreferenceYervoy (ipilimumab) [package insert]. Princeton, NJ: Bristol‐Myers Squibb Co. 2013.
dc.identifier.citedreferenceOpdivo (nivolumab) [prescribing information]. Princeton, NJ: Bristol‐Myers Squibb Co. 2014.
dc.identifier.citedreferenceKeytruda (pembrolizumab) [prescribing information]. Kenilworth, NJ: Merck & Co., Inc. 2015.
dc.identifier.citedreferenceJ Brahmer, KL Reckamp, P Baas. Nivolumab versus docetaxel in advanced squamous‐cell non‐small‐cell lung cancer. N Engl J Med. 2015; 373: 123 – 135.
dc.identifier.citedreferencePaz‐Ares L, Horn L, Borghaei H et al. Phase III, randomized trial (CheckMate 057) of nivolumab versus docetaxel in advanced non‐squamous (non‐SQ) cell non‐small cell lung cancer (NSCLC). Poster presented at: American Society of Clinical Oncology 2015 Annual Meeting; May 29‐June 2, 2015; Chicago, IL.
dc.identifier.citedreferenceBauer TM, McCleod M, Chandler JC et al. A phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non‐small cell lung cancer (NSCLC) who have progressed during or after receiving at least one prior systemic regimen. Poster presented at American Society of Clinical Oncology 2015 Annual Meeting; May 29–June 2, 2015; Chicago, IL.
dc.identifier.citedreferenceHodi FS, Postow MA, Chesney J et al. Clinical response, PFS and safety in patients with advanced melanoma receiving nivolumab combined with ipilmumuab versus ipilimumab monotherapy in CheckMate 069 study. Poster presented at: American Society of Clinical Oncology 2015 Annual Meeting; May 29‐June 2, 2015; Chicago, IL.
dc.identifier.citedreferenceU.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. Available at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010‐06‐14_QuickReference_5x7.pdf. Accessed February 8, 2016.
dc.identifier.citedreferenceR Sundar, BC Cho, JR Brahmer. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther Adv Med Oncol. 2015; 7: 85 – 96.
dc.identifier.citedreferenceSL Topalian, FS Hodi, JR Brahmer. Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer. N Engl J Med. 2012; 366: 2443 – 2454.
dc.identifier.citedreferenceJ Naidoo, DB Page, BT Li. Toxicities of the anti‐PD‐1 and anti‐PD‐L1 immune checkpoint antibodies. Ann Oncol. 2015; 26: 2375 – 2391.
dc.identifier.citedreferenceC Robert, A Ribas, JD Wolchok. Anti‐programmed‐death‐receptor‐1 treatment with pembrolizumab in ipilimumab‐refractory advanced melanoma: A randomised dose‐comparison cohort of a phase 1 trial. Lancet. 2014; 384: 1109 – 1117.
dc.identifier.citedreferenceJS Weber, SJ Antonia, SL Topalian, et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. J Clin Oncol. 2015; 33 9018a, suppl.
dc.identifier.citedreferenceBristol‐Myers Squibb Company. Risk Evaluation and Mitigation Strategy (REMS). Initial REMS approval: 03/2011; most recent modification: 02/2012. Available at http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM249435.pdf. Accessed February 8, 2016.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco1230.pdf
Size:
2.632MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.